111 related articles for article (PubMed ID: 22587385)
1. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Guérin A; Wu EQ; Bollu VK; Williams D; Guo A; de Leon DP; Quintas-Cardama A
J Med Econ; 2013; 16(1):125-33. PubMed ID: 22587385
[TBL] [Abstract][Full Text] [Related]
2. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
3. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
4. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136
[TBL] [Abstract][Full Text] [Related]
5. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
J Med Econ; 2014 Feb; 17(2):89-98. PubMed ID: 24188054
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
[TBL] [Abstract][Full Text] [Related]
7. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
McGarry LJ; Chen YJ; Divino V; Pokras S; Taylor CR; Munakata J; Nieset CC; Huang H; Jabbour E; Malone DC
Curr Med Res Opin; 2016; 32(2):289-99. PubMed ID: 26566171
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
[TBL] [Abstract][Full Text] [Related]
10. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
[TBL] [Abstract][Full Text] [Related]
14. Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S; Takaku T; Watanabe N; Iriyama N; Kimura Y; Iwanaga E; Sugimoto KJ; Mitsumori T; Ishikawa M; Nakazato T; Fujita H; Sato E; Hatta Y; Asou N; Kizaki M; Tokuhira M; Ando M; Kawaguchi T
Intern Med; 2023 Nov; 62(22):3299-3303. PubMed ID: 37005261
[TBL] [Abstract][Full Text] [Related]
15. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
McBride A; Brokars J; Reddy SR; Chang E; Tarbox MH; LeBlanc TW
Acta Haematol; 2023; 146(4):259-266. PubMed ID: 37037194
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
[TBL] [Abstract][Full Text] [Related]
17. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.
Jabbour EJ; Siegartel LR; Lin J; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2018 Oct; 21(10):1036-1040. PubMed ID: 30071761
[TBL] [Abstract][Full Text] [Related]
18. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
19. Value of survival gains in chronic myeloid leukemia.
Yin W; Penrod JR; Maclean R; Lakdawalla DN; Philipson T
Am J Manag Care; 2012 Nov; 18(11 Suppl):S257-64. PubMed ID: 23327457
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
